AU730216B2 - Solid coprecipitates for enhanced bioavailability of lipophilic substances - Google Patents

Solid coprecipitates for enhanced bioavailability of lipophilic substances Download PDF

Info

Publication number
AU730216B2
AU730216B2 AU42373/97A AU4237397A AU730216B2 AU 730216 B2 AU730216 B2 AU 730216B2 AU 42373/97 A AU42373/97 A AU 42373/97A AU 4237397 A AU4237397 A AU 4237397A AU 730216 B2 AU730216 B2 AU 730216B2
Authority
AU
Australia
Prior art keywords
composition
tpgs
solid
coprecipitate
lipophilic substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU42373/97A
Other languages
English (en)
Other versions
AU4237397A (en
Inventor
Shimon Amselem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmos Corp
Original Assignee
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL11917696A external-priority patent/IL119176A/en
Priority claimed from US08/833,076 external-priority patent/US5891469A/en
Application filed by Pharmos Corp filed Critical Pharmos Corp
Publication of AU4237397A publication Critical patent/AU4237397A/en
Application granted granted Critical
Publication of AU730216B2 publication Critical patent/AU730216B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
AU42373/97A 1996-09-01 1997-08-27 Solid coprecipitates for enhanced bioavailability of lipophilic substances Ceased AU730216B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL119176 1996-09-01
IL11917696A IL119176A (en) 1996-09-01 1996-09-01 Soluble coprecipitates for enhanced oral bioavailability of lipophilic substances
US08/833,076 US5891469A (en) 1997-04-02 1997-04-02 Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US08/833076 1997-04-02
PCT/US1997/015072 WO1998008490A1 (en) 1996-09-01 1997-08-27 Solid coprecipitates for enhanced bioavailability of lipophilic substances

Publications (2)

Publication Number Publication Date
AU4237397A AU4237397A (en) 1998-03-19
AU730216B2 true AU730216B2 (en) 2001-03-01

Family

ID=26323300

Family Applications (1)

Application Number Title Priority Date Filing Date
AU42373/97A Ceased AU730216B2 (en) 1996-09-01 1997-08-27 Solid coprecipitates for enhanced bioavailability of lipophilic substances

Country Status (5)

Country Link
EP (1) EP1017366A4 (enExample)
JP (1) JP2001523221A (enExample)
AU (1) AU730216B2 (enExample)
CA (1) CA2264718C (enExample)
WO (1) WO1998008490A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
IT1298731B1 (it) * 1998-03-13 2000-02-02 Recordati Chem Pharm Composizioni farmaceutiche contenenti complessi di inclusione con melatonina
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6200550B1 (en) * 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
US6632443B2 (en) * 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6045826A (en) * 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US20080070981A1 (en) 2000-02-23 2008-03-20 Henryk Borowy-Borowski Water-soluble compositions of bioactive lipophilic compounds
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AU2023401A (en) * 1999-12-01 2001-06-12 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
DE60111352T2 (de) * 2000-01-20 2006-05-04 Supratek Pharma, Inc., Montreal Podophyllotoxin-zusammensetzungen
DE10046541A1 (de) 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
HRP20070058B1 (hr) 2001-10-19 2014-05-23 Isotechnika Inc. Sinteza ciklosporinskih analoga
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
JP2006518380A (ja) 2003-01-31 2006-08-10 スミスクライン・ビーチャム・コーポレイション 固体分散体組成物
CN1758901B (zh) * 2003-02-19 2010-04-28 生命周期药物公司 硅石或硅石衍生物作为吸附材料的用途
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20070149509A1 (en) * 2003-12-18 2007-06-28 Luca Barella Use of vitamin e
WO2006036614A2 (en) * 2004-09-24 2006-04-06 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials comprising vitamin e tpgs and a water soluble polymer
CN101031284A (zh) * 2004-09-30 2007-09-05 伊斯曼化学公司 使亲脂性药物增溶而无显著外排抑制作用的含有维生素e tpgs分子的药物制剂和该制剂的用途
US20060088591A1 (en) * 2004-10-22 2006-04-27 Jinghua Yuan Tablets from a poorly compressible substance
US8067380B2 (en) 2005-12-19 2011-11-29 Industrial Technology Research Institute Glutathione-based delivery system
US7446096B2 (en) * 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system
WO2008007728A1 (fr) * 2006-07-13 2008-01-17 Kaneka Corporation Préparation orale contenue dans une structure à membrane lipidique, et agent contre la fatigue comprenant une coenzyme comme ingrédient actif
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
JP5437232B2 (ja) * 2008-03-11 2014-03-12 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
MX2010010050A (es) 2008-03-20 2011-03-15 Virun Inc Star Emulsiones que incluyen un derivado de polietilen glicol de tocoferol.
BRPI0909185A2 (pt) 2008-03-20 2015-08-25 Virun Inc Derivado de vitamina e e seus usos
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
JPWO2010092925A1 (ja) * 2009-02-12 2012-08-16 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
EP2563164B1 (en) 2010-03-23 2016-06-29 Virun, Inc. Nanoemulsion including sucrose fatty acid ester
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
ITMI20112042A1 (it) * 2011-11-10 2013-05-11 Eratech S R L Polvere da ricostituire prima dell'uso comprendente melatonina e preparazione iniettabile ottenibile da tale polvere.
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
FR2999081B1 (fr) * 2012-12-06 2015-02-27 Hra Pharma Lab Dispersion solide d'un modulateur selectif du recepteur a la progesterone
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
HUP1300647A2 (hu) * 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US12544389B2 (en) 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations
GB201410869D0 (en) * 2014-06-18 2014-07-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontal disease
WO2016044813A1 (en) 2014-09-18 2016-03-24 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
DK3302437T4 (da) * 2015-05-28 2026-02-23 Fresh Cut Dev Llc Stabile cannabinoidformuleringer
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
EA201991641A1 (ru) * 2017-01-03 2020-03-10 Ресептор Холдингз, Инк. Лекарственные соединения и пищевые добавки
WO2018152334A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
CN108245683B (zh) * 2018-01-26 2020-02-14 华中科技大学 一种具有p-糖蛋白抑制功能的抗肿瘤前药及制备方法
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
JP2023507430A (ja) * 2019-12-20 2023-02-22 イドルシア ファーマスーティカルズ リミテッド Ｎ－［１－（５－シアノ－ピリジン－２－イルメチル）－１ｈ－ピラゾール－３－イル］－２－［４－（１－トリフルオロメチル－シクロプロピル）－フェニル］－アセトアミドを含む薬学的組成物
KR20220119024A (ko) 2019-12-20 2022-08-26 인터벳 인터내셔널 비.브이. 피라졸 제약 조성물
CN115867285A (zh) * 2020-03-19 2023-03-28 Ac免疫有限公司 Tau蛋白病的剂量治疗
US12636257B2 (en) * 2021-04-17 2026-05-26 Bhami's Research Laboratory, Pvt. Ltd. Polypeptide formulations comprising crystal or amorphous polypeptides and vitamin E
IT202200002528A1 (it) * 2022-02-11 2023-08-11 Pierpaoli Exelyas S R L Composizione comprendente melatonina ad alta biodisponibilità

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3102078A (en) * 1961-01-13 1963-08-27 Eastman Kodak Co Water-dispersible vitamin preparations
US5179122A (en) * 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3673163A (en) * 1970-06-16 1972-06-27 Lilly Co Eli Pharmacological preparation containing an acronycine-polyvinylprrolidone coprecipitate
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
US4327080A (en) * 1981-07-13 1982-04-27 E. R. Squibb & Sons, Inc. Novel Bendroflumethiazide formulations and method
US4758427A (en) * 1985-08-08 1988-07-19 Ciba-Geigy Corporation Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US5234696A (en) * 1991-12-27 1993-08-10 Abbott Laboratories Method of producing tablets, tablets produced thereby, and method of treatment using same
IT1255792B (it) * 1992-08-05 1995-11-16 Bayer Italia Spa Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
EP0825849A1 (en) * 1995-05-19 1998-03-04 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3102078A (en) * 1961-01-13 1963-08-27 Eastman Kodak Co Water-dispersible vitamin preparations
US5179122A (en) * 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems

Also Published As

Publication number Publication date
WO1998008490A1 (en) 1998-03-05
JP2001523221A (ja) 2001-11-20
EP1017366A4 (en) 2006-03-22
CA2264718C (en) 2006-05-30
AU4237397A (en) 1998-03-19
EP1017366A1 (en) 2000-07-12
CA2264718A1 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
US5891469A (en) Solid Coprecipitates for enhanced bioavailability of lipophilic substances
CA2264718C (en) Solid coprecipitates for enhanced bioavailability of lipophilic substances
AU722217B2 (en) Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
US20250090499A1 (en) Compositions and methods for improving bone health using self-emulsifying formulations of diindolylmethane
KR100425755B1 (ko) 이트라코나졸을 함유하는 조성물 및 그 제조방법
JPH08509475A (ja) アルコール及び疎水性薬物を含有する医薬として許容された改良組成物
US20120225118A1 (en) Compositions for delivery of insoluble agents
JP2001505928A (ja) シクロスポリン及び陰イオン性界面活性剤を含む固体医薬組成物
WO2009092291A1 (zh) 一种给药系统及其制备方法和应用
JP2010090132A (ja) 流動床噴霧乾燥によるナノ粒子製造方法
JP4721640B2 (ja) フェノフィブラートのナノ粒子製剤
TW201444586A (zh) 乳液調配物
US20040180961A1 (en) Compositions and preparation methods for bioavailable oral aceclofenac dosage forms
IL299941A (en) Pharmaceutical compositions with improved delivery of lipophilic active substances
KR20090086281A (ko) 발사르탄의 마이크로에멀젼 투여 형태 및 이의 제조 방법
CN100536921C (zh) 过饱和阳离子自乳化给药系统及其制备方法
JPH07121858B2 (ja) 熱で脱水したエマルジョン組成物
MX2007007887A (es) Sistema galenico novedoso para transporte del principio activo, metodo de preparacion y uso.
IL119176A (en) Soluble coprecipitates for enhanced oral bioavailability of lipophilic substances
JP2006509785A (ja) ビフェニルジメチルジカルボン酸の経口用マイクロエマルション組成物
KR100352089B1 (ko) 페노피브레이트를 함유하는 경구용 마이크로에멀젼 조성물
CA2251194C (en) Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
KR100455216B1 (ko) 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법
IL126384A (en) Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
SI26054A (sl) Supernasičljiv brez olja samo-nanoemulgirni sistem za dovajanje zdravil - SNEDDS za v vodi slabo topne farmacevtske sestavine in postopek njegove priprave

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)